Anzeigenschluss: 19.11.2024
Erscheinungstermin: 12.12.2024
Schwerpunkt: Liquid Biopsy
Editorial
G. Schuch
Beitrag 1
M. Janning
Liquid Biopsy beim NSCLC
Beitrag 2
K. Clemm von Hohenburg
Liquid Biopsy in der Hämatologie
Beitrag 3
N.N.
Liquid Biopsy in der HNO
Journal Club
Brustkrebs
Bardia et al.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer (+ Kommentar von Andreas Schalhorn)
Endometrium-Karzinom
Colombo et al.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial (+ Kommentar von Michael Eichbaum)
Hepatozelluläres Karzinom
Rodriguez et al.
Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease
NSCLC
Lu et al.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Melanoma
Wolchok et al.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (+ Kommentar von Andreas Schalhorn)
Neues aus der Forschung
Leukämie
Tix et al.
Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients.
Brustkrebs
Kiser et al.
Screening Familial Risk for Hereditary Breast and Ovarian Cancer.
NSCLC
Han et al.
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial.
Leberzellkarzinom
Dawson et al.
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study
CME-Fortbildung
Leberzellkarzinom
A. Kobe
Leberzellkarzinom
Onkologie aktuell
Lymphome
Kongressbericht: ISHL (International Symposium on Hodgkin Lymphoma)
Allgemeine Onkologie
Kongressbericht: ESMO-Kongress
*Die Redaktion behält sich aktuelle Änderungen vor.